Browse medicines, page 3 of 10
Some records contain detailed evidence; others currently contain only basic identity and regulatory information. Reviewed conclusions appear only when they are available for a specific use and group of people.
Showing 121–180 of 546 records
Glutathione Peroxidase
Protein medicineDietary supplement; not FDA-approved as a medicineExpanded recordGolimumab-Sldi (Immgolis / Immgolis Intri)
Protein medicineApproved in the United States (FDA)Expanded recordGulonolactone Oxidase
Protein medicineDietary supplement; not FDA-approved as a medicineExpanded recordHepatitis B Virus Subtype Adw2 Hbsag Surface Protein Antigen (Engerix-B)
Protein medicineLaboratory or animal-stage researchExpanded recordHuman Immunoglobulin G (Octagam Immune Globulin (Human) / Panzyga / Hizentra / Cutaquig / Privigen / Gammaplex)
Protein medicineLaboratory or animal-stage researchExpanded recordUse listed on the medicine record
Adults and pediatric patients 2 years of age and older with primary humoral immunodeficiency
Human Papillomavirus Type 33 L1 Capsid Protein Antigen (Gardasil 9)
Protein medicineLaboratory or animal-stage researchExpanded recordHuman Papillomavirus Type 45 L1 Capsid Protein Antigen (Gardasil 9)
Protein medicineLaboratory or animal-stage researchExpanded recordHuman Rho Immune Globulin (Winrho Sdf / Hyperrho Full Dose / Rhogam Ultra-Filtered Plus / Hyperrho Mini-Dose / Rhophylac)
Protein medicineLaboratory or animal-stage researchExpanded recordHyaluronidase (Vitrase / Amphadase / Hydase / Hylenex Recombinant)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
Amphadase ® is an endoglycosidase indicated as an adjuvant: • in subcutaneous fluid administration for achieving hydration ( 1.1 ) • to increase absorption and dispersion of other injected drugs ( 1.2 ) • in subcutaneous urography for improving resorption of radiopaque agents ( 1.3 ) 1.1 Subcutaneous Fluid Administration Amphadase ® is indicated as an adjuvant in subcutaneous fluid administration for achieving hydration. 1.2 Dispersion and Absorption of Injected Drugs Amphadase ® is indicated as an adjuvant to increase the dispersion and absorption of other injected drugs.
Hyaluronidase-Nvhy (Opdivo Qvantig)
Protein medicineApproved in the United States (FDA)Expanded recordHydrolyzed Bovine Elastin (Base (Anubis Barcelona / Massage Cream For Stretch Marks / Anubis Barcelona Vital Line)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
INDICATIONS& USAGE Suitable for all types of skin damage due to stretching of the skin. Apply all over skin, concentrating on tummy, hips, thighs and bust.Massage liberally into skin twice daily.
Infliximab-Qbtx (Ixifi)
Protein medicineApproved in the United States (FDA)Expanded recordInotuzumab Ozogamicin (Besponsa)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
Relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia
Insulin Aspart-Fsan (Garzulys)
Protein medicineApproved in the United States (FDA)Expanded recordInsulin-Like Growth Factor
Protein medicineDietary supplement; not FDA-approved as a medicineExpanded recordInsulin-Like Growth Factor 1 Receptor (Dr Dale Wellness Nu Fem 1 2 3 All in One Topical Homeopathic)
Protein medicineDietary supplement; not FDA-approved as a medicineExpanded recordUse listed on the medicine record
Topical gel, applied to skin
Insulin-Like Growth Factor-2 (Dr Dale Wellness Nu Fem 1 2 3 All in One Topical Homeopathic)
Protein medicineDietary supplement; not FDA-approved as a medicineExpanded recordUse listed on the medicine record
Topical gel, applied to skin
Islelizumab-Jsgr (Tevimbra)
Protein medicineApproved in the United States (FDA)Expanded recordLapine T-Lymphocyte Immune Globulin (Thymoglobulin)
Protein medicineLaboratory or animal-stage researchExpanded recordUse listed on the medicine record
The prophylaxis and treatment of acute rejection
Margetuximab-Cmkb (Margenza)
Protein medicineApproved in the United States (FDA)Expanded recordOxidase
Protein medicineDietary supplement; not FDA-approved as a medicineExpanded recordPancrelipase Protease (Creon / Zenpep / Pancreaze / Pertzye / Viokace)
Protein medicineLaboratory or animal-stage researchExpanded recordUse listed on the medicine record
Exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatectomy
Phosphatase
Protein medicineDietary supplement; not FDA-approved as a medicineExpanded recordPivekimab Sunirine (Decnupaz)
Protein medicineLaboratory or animal-stage researchExpanded recordUse listed on the medicine record
Blastic plasmacytoid dendritic cell neoplasm
Rilonacept (Arcalyst)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS), and Muckle-Wells Syndrome
Sodium Chloride (Sodium Chloride 0.9% in Plastic Container / Natrum Muriaticum / Sodium Chloride 0.45% in Plastic Container / Bacteriostatic Sodium Chloride 0.9% in Plastic Container / Bacteriostatic Sodium Chloride / Resp Ease)
Protein medicineApproved in the United States (FDA)Expanded recordStreptococcus Pneumoniae Type 11a Capsular Polysaccharide Diphtheria Crm197 Protein Conjugate Antigen (Capvaxive / Prevnar 20)
Protein medicineLaboratory or animal-stage researchExpanded recordAlbumin Human (Albutein / Plasbumin / Albuked / Flexbumin / Albuminex / Alburx)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
And children
Asfotase alfa (Strensiq)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
Perinatal/infantile- and juvenile-onset hypophosphatasia
Asparaginase Erwinia Chrysanthemi -Rywn (Rylaze)
Protein medicineApproved in the United States (FDA)Expanded recordAvalglucosidase alfa (Nexviazyme)
Protein medicineLaboratory or animal-stage researchExpanded recordUse listed on the medicine record
Patients 1 year of age and older with late-onset Pompe disease
Beractant (Survanta)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
Prevention and treatment (“rescue”) of Respiratory Distress Syndrome (RDS) (hyaline membrane disease) in premature infants
Bevacizumab-Vikg (Lytenava)
Protein medicineApproved in the United States (FDA)Expanded recordBrolucizumab-Dbll (Beovu)
Protein medicineApproved in the United States (FDA)Expanded recordBulevirtide-Gmod (Hepcludex)
Protein medicineApproved in the United States (FDA)Expanded recordCenegermin (Oxervate)
Protein medicineLaboratory or animal-stage researchExpanded recordUse listed on the medicine record
Neurotrophic keratitis
Cenegermin-Bkbj (Oxervate)
Protein medicineApproved in the United States (FDA)Expanded recordChoriogonadotropin alfa (Ovidrel)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
The induction of final follicular maturation and early luteinization in infertile women who have undergone pituitary desensitization and who
Cipaglucosidase Alfa-Atga (Pombiliti)
Protein medicineApproved in the United States (FDA)Expanded recordCoagulation Factor X Human (Balfaxar)
Protein medicineLaboratory or animal-stage researchExpanded recordUse listed on the medicine record
Hereditary Factor X deficiency
Corynebacterium Diphtheriae Crm197 Protein (Vaxneuvance / Capvaxive)
Protein medicineLaboratory or animal-stage researchExpanded recordDatopotamab Deruxtecan (Datroway)
Protein medicineLaboratory or animal-stage researchExpanded recordUse listed on the medicine record
DATROWAY is a Trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of: adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) who have received prior EGFR-directed therapy and platinum-based chemotherapy. ( 1.1 ) This indication is approved under accelerated approval based on objective response rate and duration of response [see Clinical Studies (14.1) ] .
Decarboxylase
Protein medicineDietary supplement; not FDA-approved as a medicineExpanded recordDenosumab-Mobz (Boncresa / Oziltus)
Protein medicineApproved in the United States (FDA)Expanded recordDenosumab-Qbde (Enoby / Xtrenbo)
Protein medicineApproved in the United States (FDA)Expanded recordDipeptigylpeptidase
Protein medicineDietary supplement; not FDA-approved as a medicineExpanded recordDonanemab-Azbt (Kisunla)
Protein medicineApproved in the United States (FDA)Expanded recordEfbemalenograstim alfa (Ryzneuta)
Protein medicineLaboratory or animal-stage researchExpanded recordUse listed on the medicine record
RYZNEUTA is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. Limitations of Use RYZNEUTA is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation.
Elapegademase (Revcovi)
Protein medicineLaboratory or animal-stage researchExpanded recordUse listed on the medicine record
Adenosine deaminase severe combined immune deficiency
Enfortumab Vedotin (Padcev Ejfv)
Protein medicineLaboratory or animal-stage researchExpanded recordUse listed on the medicine record
Muscle invasive bladder cancer
Epoetin Alfa-Epbx (Retacrit)
Protein medicineApproved in the United States (FDA)Expanded recordFibrinolysin (Elase-Chloromycetin)
Protein medicineApproved in the United States (FDA)Expanded recordHeartsease
Protein medicineDietary supplement; not FDA-approved as a medicineExpanded recordHemicellulase
Protein medicineDietary supplement; not FDA-approved as a medicineExpanded recordHemin (Panhematin)
Protein medicineLaboratory or animal-stage researchExpanded recordUse listed on the medicine record
The amelioration of recurrent attacks of acute intermittent porphyria temporally related to the menstrual cycle in susceptible women, after
Human Hepatitis B Virus Immune Globulin (Hepagam B / Nabi-Hb / Hyperhep B)
Protein medicineLaboratory or animal-stage researchExpanded recordUse listed on the medicine record
Nabi-HB, Hepatitis B Immune Globulin (Human), is indicated for treatment of acute exposure to blood containing HBsAg, perinatal exposure of infants born to HBsAg-positive mothers, sexual exposure to HBsAg-positive persons and household exposure to persons with acute HBV infec- tion in the following settings: Acute Exposure to Blood Containing HBsAg: Following either parenteral exposure (needlestick, bite, sharps), direct mucous membrane contact (accidental splash), or oral ingestion (pipetting accident), involving HBsAg-positive materials such as blood, plasma, or serum.
Human Papillomavirus Type 11 L1 Capsid Protein Antigen (Gardasil 9 / Gardasil)
Protein medicineLaboratory or animal-stage researchExpanded recordHuman Papillomavirus Type 31 L1 Capsid Protein Antigen (Gardasil 9)
Protein medicineLaboratory or animal-stage researchExpanded recordHuman Papillomavirus Type 6 L1 Capsid Protein Antigen (Gardasil 9 / Gardasil)
Protein medicineLaboratory or animal-stage researchExpanded recordHuman Rotavirus A Type G1p7 Strain Wi79 Live Antigen (Rotateq)
Protein medicineLaboratory or animal-stage researchExpanded record